MNMD Stock Forecast 2025 To 2030 And Price Prediction

Psychedelic stock prices are predicted to climb by 13.5% annually through 2029, which speaks well for the sector. Psychedelic drugs have gained popularity in the field of mental health. So, that growth will undoubtedly attract investment money that aims to capitalize on that growth.

Consumer interest in mental health is rising, and general awareness is increasing as well. Advocates for mental health have long praised their advantages and urged their acceptance by the general public. Pharmaceutical companies and conventional healthcare providers have figured it out and joined the trend. Because of this, early psychedelic stock investments could be quite profitable.

A biopharmaceutical business called Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is in the clinical stages of developing medications and treatments based on psychoactive drugs. The price of MNMD stock as of September 7, 2023, is $4.10. In the last month, it has moved by -5.75%; on the last day, MNMD has risen by +3.27%.

Do you wish to invest in Mind Medicine stocks or already have some in your portfolio? If so, you can discover important information about Mind Medicine’s (MindMed) stock price dynamics in 2025 in this article. Let us know the value of a Mind Medicine share in 2025.

About Mind Medicine Inc. (MindMed) (NASDAQ: MNMD) Stock

Mind Medicine (MindMed), Inc., the neuro-pharmaceutical business discovers, produces, and utilizes psychedelic medications. The company creates cutting-edge goods, such as psychoactive drugs and digital medicine, to treat neurological, psychiatric, and addictive problems of the brain. Digital treatment, a budding sector, involves using technology to assess and act in the interest of human health.

The company is testing ten substances in preclinical or clinical studies. Also, four are expected to move on to Phase 1. Stephen L. Hurst, Scott M. Freeman, Leonard Latchman, and Jamon Alexander Rahn started the business in 2019, based in New York, NY.

The potential therapies in Mind Medicine’s pipeline are supported by innovative research. They more than imply that the use of psychoactive drugs can be employed to treat anxiety and stress-related brain diseases. These medications have a wide range of potential applications. This includes the treatment of PTSD-related stress and anxiety as well as secondary stress disorders associated with the care of those with stress- and anxiety-related disorders. Autism, pain, and social difficulties have all been treated using psychoactive substances.

The benefits of using psychoactive substances over traditional medicines include faster efficacy and fewer adverse effects. It may take weeks for some current treatments to start working. However psychoactive medications can have a favorable impact on patients after just one use. Also, the adverse effects of current therapies are extensive. Increased suicidal behavior is sometimes one of the side effects of mainstream treatments.

Mind Medicine (MindMed) Financials

On August 29, 2023, the opening price of MNMD shares was $3.81. The cost of mind medicine has fluctuated between $2.12 and $12.88 over the past year. The company has a $151.33 million market capitalization, a price-to-earnings ratio of -1.91, and a beta of 2.15. The company’s fifty-day and 200-day moving averages are $4.08 and $3.65, respectively.

On August 3, Mind Medicine released its most recent earnings report. The company’s ($0.72) earnings per share (EPS) for the quarter came in below analysts’ consensus forecasts of ($0.54). Investment strategists predict that Mind Medicine will report -2.49 earnings per share for the current year.

“Buy” for Mind Medicine Inc. shares

According to the study, the eight brokerages that cover Mind Medicine Inc. have collectively given the company a “buy” recommendation. A buy rating has been assigned to the stock by eight equity research analysts. Brokerages that have modified their stock coverage in the past year have an average 12-month price objective of $22.67.

Recently, several brokerages have commented on MNMD. In a research note published on August 4, 2023, Royal Bank of Canada raised their price objective on shares of Mind Medicine from $5.00 to $7.00. They assigned the stock an “outperform” rating.

In a report on August 4, HC Wainwright restated a “buy” rating. It set a $75.00 price target on shares of Mind Medicine. In research released on Tuesday, August 22, Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Mind Medicine.

Green Day for stock of Mind Medicine Inc.(MNMD)

On the last trading day (Wednesday, September 6, 2023), the price of Mind Medicine (MindMed) Inc. Subordinate stock increased by 3.27%. It moved from $3.97 to $4.10. The stock’s latest trading day saw 4.57% of its daily range between a low of $3.94 and a high of $4.12. The price has decreased in six of the previous ten days, dropping -0.24% overall.

The last day of trading saw a 106 thousand share decrease in volume, and 283 thousand shares were purchased and sold for a total transaction value of almost $1.16 million. Investors should be aware that divergence is caused by declining volume at higher prices. It may serve as a precursor to changes over the coming days.

In the near term, the stock is in the middle of an extensive and robust rising trend, and a rise within the movement is projected. Given the short-term trend, the stock will be expected to increase 13.71% over the next three months and, with a 90% likelihood, hold a price between $4.28 and $5.90 at the end of this time frame.

MNMD signals and forecast

Today’s stock market is sending conflicting signals. The short-term moving average has a buy signal for Mind Medicine Inc.’s subordinate stock. But the long-term average has a general sell signal. Given that the long-term average exceeds the short-term average, the stock has a general sell signal. This indicates a less hopeful future for the stock.

The long-term moving average of $4.25 will act as a barrier for the stock if it rises. The short-term average of $3.98 will provide some support if the price falls. Another purchase signal will be given if the long-term average is broken, while another sell signal will be added if the short-term average is broken. Thus, it strengthens the overall movement.

On Monday, July 31, 2023, a sell signal was generated from a pivot top point; thus far, it has plunged -16.84%. Until a new bottom pivot has been discovered, more decline is predicted. The price rose during the most recent trading day while volume decreased. This results in a divergence and may or may not be seen as an early warning. Additionally, the 3-month moving average convergence divergence (MACD) has generated a buy signal.

Performance of MNMD stock

A subordinate of Mind Medicine Inc. finds support from accumulated volume at $4.03. This price point may present a buying opportunity. An upward reaction is likely to occur when the asset is tested.

The daytime fluctuations of this stock are typical. But you should be cautious if volume is low or declining because it raises the risk. The stock fluctuated by $0.180, or 4.57%, between high and down over the previous day. The stock’s daily average volatility in the last week was 5.48%.

18.41 million shares were purchased, and 4.37 million shares were sold in the most recent 100 deals. Thirteen days ago, Greenway Schond L. sold 20,000 shares in the most recent transaction. Insiders appear to believe there is substantial upside potential based on the size of the stock purchases relative to sales. The due date for stock options can occasionally be used as a reason for more significant purchases.

Mind Medicine Mindmed Stock (MNMD) Price History

The 30-day stock price prediction for Mind Medicine (MindMed) Inc. is based on upward and downward trends during the previous 30 days. In the past 30 days, MNMD stock experienced 6.91% price volatility and 10/30 (33%) green days.

It’s helpful to also look at the price history of Mind Medicine (MindMed) Inc. to get a better picture of what might happen to the MNMD stock price in the future. The shares of Mind Medicine Inc. performed -6.24% worse than Ethereum and -27.07% worse than Bitcoin over the past year.

 Here’s a table of 14-day historical data for MNMD stock:

DateOpening priceClosing priceMinimum priceMaximum price

Mind Medicine (MindMed) Stock Forecast 2023

In this extensive study, we thoroughly review the price changes in Mind Medicine stock over the years. Investors can learn much about the historical performance and volatility of MNMD shares by examining the year-by-year statistics. This thorough analysis of Mind Medicine’s stock price history offers a basis for knowing how the company’s stock has changed over time, from key milestones and volatility to significant trends.

Here’s a table of Mind Medicine’s (MindMed) stock price history for the year 2023:

DateHighLowHigh – LowVolume% Change
Sep, 20234.323.930.39001,425,158-1.20%
Aug, 20235.003.721.2810,812,921-15.8%
Jul, 20235.013.511.5016,630,784+38.1%
Jun, 20233.883.090.79509,656,743+0.85%
May, 20233.882.980.90096,959,487-7.33%
Apr, 20233.992.861.1311,353,612+20.5%
Mar, 20233.792.820.97006,775,040-14.8%
Feb, 20234.283.320.960012,553,660+9.09%
Jan, 20233.772.201.5712,172,000+55.0%

Here’s a table for Mind Medicine (MindMed) stock (MNMD) price history for the year 2022:

DateHighLowHigh – LowVolume% Change
Dec, 20222.872.120.750013,754,212-13.7%
Nov, 20223.102.350.750010,507,786-13.0%
Oct, 20223.542.580.960019,336,180-16.3%
Sep, 202212.632.859.7835,897,956-70.1%
Aug, 202219.957.9512.0036,631,853+12.5%
Jul, 202211.708.703.002,136,283+8.53%
Jun, 202215.759.476.286,097,977-29.2%
May, 2022207.310.52196.83,248,759+13.1%
Apr, 202217.2511.855.403,346,328-27.9%
Mar, 202219.0513.655.403,962,399-9.02%
Feb, 202222.2014.707.505,690,878+8.93%
Jan, 202223.1011.8511.258,909,613-18.8%

MNMD cost $3.86 at the same time last month. It is now at $4.10 after moving -5.75% in the previous month. MNMD has pumped by +3.27% over the last 24 hours. But the long-term outlook is still positive. The law of supply and demand causes short-term ups and downs in the price of Mind Medicine stock.

Here’s a table for the Mind Medicine Inc Stock Price Forecast for 2023:

October 20233.3813.3303.2573.411-1.55% ▼
November 20233.3043.3103.1393.3100.19% ▲
December 20233.3193.5543.3193.5656.6% ▲

This table provides the high, low, open, and close prices for Mind Medicine Inc. stock for October, November, and December 2023, along with the percentage change in each month’s closing price.

The Change column shows the stock’s closing price as a percentage change from the previous month. It states whether the stock price is expected to rise or fall during the month. An expected price increase is indicated by a positive percentage( ▲), while a negative percentage shows a scheduled price decrease (▼).

Mind Medicine Mindmed Stock (MNMD) Price Forecast for 2024

Before making any investments, it’s crucial to do extensive research. If necessary, consult with a financial advisor. A stock’s value should not be determined solely by historical price data. Previous performance is only sometimes a reliable predictor of future outcomes.

According to available information, the market environment for Mind Medicine’s MNMD shares and possibly its market cycle have been bearish for the past 12 months. There is a tendency for stocks in the manufacturing sector to be less popular at this time of year.

Here’s a table for the Mind Medicine Inc. stock price forecast for January to December 2024:

January 20243.6143.8783.5993.8996.8% ▲
February 20243.8894.2983.8894.2989.5% ▲
March 20244.3003.9983.9984.350-7.55% ▼
April 20244.0083.8393.8394.008-4.39% ▼
May 20243.8173.7053.6443.817-3.03% ▼
June 20243.7713.7383.7373.821-0.87% ▼
July 20243.7963.8683.7844.1311.88% ▲
August 20243.8374.8803.6194.88021.38% ▲
September 20245.1274.1824.1825.320-22.6% ▼
October 20244.1214.0674.0044.162-1.32% ▼
November 20244.0454.0533.8924.0530.22% ▲
December 20244.1374.3434.1294.3584.73% ▲

The above table provides the high, low, open, and close prices for Mind Medicine Inc. stock for each month in 2024 and the percentage change in each month’s closing price.

Mind Medicine Mindmed Stock (MNMD) Price Forecast for 2025

It’s essential to remember that our suggested information is hypothetical. Also, it shouldn’t be applied when choosing real investments. Forecasts for stocks are highly unreliable and subject to a variety of variables. It includes market conditions, current economic conditions, corporate performance, and new developments. Before making an investment decision, investors should perform extensive research and keep other relevant details in mind.

The projection for Mind Medicine Inc.’s (MNMD) stock price for each month of 2025 is shown in the table.

January 20254.3414.6354.3414.6456.35% ▲
February 20254.6945.0434.6775.0436.92% ▲
March 20255.1004.7724.7665.100-6.89% ▼
April 20254.7404.5864.5864.740-3.37% ▼
May 20254.5794.4474.3974.579-2.98% ▼
June 20254.5134.5394.4904.5720.57% ▲
July 20254.5244.6374.5244.8922.44% ▲
August 20254.5945.5314.3875.53116.95% ▲
September 20255.8014.9234.9236.075-17.83% ▼
October 20254.8734.8194.7564.909-1.13% ▼
November 20254.8064.7874.6474.806-0.39% ▼
December 20254.8725.0844.8655.1034.17% ▲

Based on our analysis, the MNMD shares may be a wise investment and a way to make money in the future, according to our stock experts, who predict a positive trend. This stock has a promising future, so we advise adding it to your portfolio. 

Who are the major holders of MNMD shares?

Eighty-three institutional investors and hedge funds owned Mind Medicine (MindMed) shares over the previous two years. Institutional investors who made the most significant investments were:

  • Alyeska Investment Group L.P. ($2.42 million),
  • BlackRock Inc. ($1.98 million),
  • Geode Capital Management LLC ($1.33 million), 
  • Merit Financial Group LLC ($1.19 million), 
  • Busey Wealth Management ($0.86 million), 
  • Deutsche Bank AG ($0.73 million), and
  • Empery Asset Management L.P. ($0.66 million)

How much revenue does Mind Medicine (MindMed) bring in annually?

The recorded net income for Mind Medicine (MindMed) (NASDAQ: MNMD) is -$56.80 million. Over the previous four quarters, MNMD’s earnings per share were -$1.99.

When will Mind Medicine (MindMed) report earnings?

According to the report dated from the previous year, Mind Medicine’s (MindMed) expected earnings date is Thursday, November 9, 2023. The company still needs to confirm the date of its upcoming earnings release.

Are Wall Street analysts recommending that you buy Mind Medicine stock in 2023?

The five Wall Street analysts who cover MNMD shares concur that the stock should be strongly purchased. Out of five analysts, two (40%) suggest MNMD as a strong buy, three (60%) recommend MNMD as a buy, zero (%) recommend MNMD as a hold, zero (%) recommend MNMD as a sell, and zero (%) recommend MNMD as a strong sell.


In comparison to current methods like antidepressants and psychotherapy, Mind Medicine expects that the innovative therapies it is developing will offer more advantages and fewer adverse effects. The company is now hiring for clinical studies throughout the U.S. and Switzerland.

Even if it lags COMPASS Pathways in terms of that pipeline, it offers similar potential in that share values might increase by a factor of 3. The fact that Mind Medicine now anticipates that its cash runway will extend into the first half of 2025 is also significant to note. That should enable it to pass crucial clinical outcomes, which, if positive, promise to trigger price hikes.

Next Post
Is Dillard’s going out of business in 2024?

Must Read